---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015232"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:43:38.673022+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences: BEACON Phase 3 tarcocimab meets primary endpoint in retinal vein occlusion

## Summary
- BEACON Phase 3 randomized 568 RVO patients to tarcocimab 5 mg q8w after 2 monthly loads vs aflibercept 2 mg q4w.
- Primary endpoint of non-inferior BCVA change at week 24 met in BRVO (p=0.0004) and overall RVO (p=0.0243).
- Tarcocimab dosed 4 times vs aflibercept 6 times in first 24 weeks, showing extended durability.
- Safety favorable: low intraocular inflammation (1.4% vs 0.4%); no vasculitis or retinal artery occlusion.
- Full primary results to be presented at ophthalmology congresses in September 2022.

## SEC filing metadata
- accession: 0000950170-22-015232
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017022015232/0000950170-22-015232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017022015232/kod-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015232
- JSON: https://secwatch.observer/filing/0000950170-22-015232.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.